Welcome to our dedicated page for Travere Therapeutics news (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics stock.
Travere Therapeutics Inc (TVTX) is a biopharmaceutical innovator developing therapies for rare kidney, liver, and metabolic diseases. This page provides a comprehensive repository of official company announcements, clinical trial updates, and regulatory developments.
Investors and researchers will find curated press releases detailing milestones for pipeline candidates like FILSPARI and sparsentan, along with financial disclosures and partnership announcements. Content is organized to highlight material events including FDA communications, trial phase completions, and strategic collaborations.
All updates are sourced directly from Travere Therapeutics to ensure accuracy. Bookmark this page for efficient tracking of the company’s progress in advancing treatments for IgA nephropathy, FSGS, and other rare conditions.
Travere Therapeutics (TVTX) has announced plans to submit a supplemental New Drug Application (sNDA) for FILSPARI to treat focal segmental glomerulosclerosis (FSGS), following a successful Type C meeting with the FDA. The submission, expected around the end of Q1 2025, will be based on data from Phase 3 DUPLEX and Phase 2 DUET studies.
If approved, FILSPARI could become the first approved medicine for FSGS, a rare kidney disorder affecting over 40,000 adults and children in the U.S. The submission is supported by recent findings from the PARASOL workgroup, which confirmed that reduction in proteinuria over 24 months is strongly associated with reduced risk of kidney failure in FSGS patients.
Travere Therapeutics (NASDAQ: TVTX) reported strong Q4 2024 performance with 693 new patient start forms for FILSPARI and approximately $50 million in FILSPARI net product sales. Total net product sales for Q4 2024 reached approximately $74 million, with full-year 2024 sales at $227 million. The company ended 2024 with $371 million in cash and equivalents.
The FDA accepted Travere's sNDA for FILSPARI liver monitoring modification in IgAN with a PDUFA date of August 28, 2025. FILSPARI has launched in Germany, Austria, Switzerland, and received UK approval. The company expects its European conditional marketing authorization to convert to full approval in 2025, triggering a $17.5 million milestone payment from CSL Vifor.
Partner Renalys Pharma expects topline results from its Phase 3 sparsentan trial for IgAN in Japan in H2 2025. The company plans to update on FSGS regulatory pathway by Q4 2024 earnings call, while the Phase 3 HARMONY Study enrollment for pegtibatinase in HCU will restart in 2026.
Travere Therapeutics (NASDAQ: TVTX) has announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. The company's president and CEO, Eric Dube, Ph.D., is scheduled to deliver a presentation on Tuesday, January 14, 2025, at 8:15 a.m. PT.
The presentation will be accessible through a live webcast on the Investor page of Travere's website at ir.travere.com/events-presentations. For those unable to attend live, a replay of the presentation will remain available on the website for up to 30 days after the event.
Travere Therapeutics (NASDAQ: TVTX) has announced its participation in two major investor conferences in December 2024. The company will present at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3, at 10:00 a.m. ET, and the Citi 2024 Global Healthcare Conference on Wednesday, December 4, at 2:30 p.m. ET. Live webcasts will be available on Travere's investor relations website, with replays accessible for 30 days after each event.
Travere Therapeutics (NASDAQ: TVTX) announced that its Board's Compensation Committee granted inducement equity grants to six new employees on November 10, 2024. The grants consist of restricted stock units (RSUs) covering 24,400 shares of common stock. While subject to the company's 2018 Equity Incentive Plan terms, these RSUs were granted outside the plan as employment inducements under Nasdaq Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting annually, contingent on continued employment.
Travere Therapeutics has completed its previously announced public offering of 8,984,375 shares of common stock at $16.00 per share, including 1,171,875 shares from the full exercise of underwriters' option. The offering generated gross proceeds of approximately $143.8 million before deducting underwriting discounts and expenses. Jefferies and Leerink Partners served as joint book-running managers, with Wedbush PacGrow as co-manager. The offering was made pursuant to a shelf registration statement that became effective on August 1, 2024.
Travere Therapeutics (Nasdaq: TVTX) has announced the pricing of a public offering of 7,812,500 shares of common stock at $16.00 per share. The offering is expected to generate gross proceeds of $125.0 million before deducting underwriting costs and expenses. The company has granted underwriters a 30-day option to purchase up to an additional 1,171,875 shares. The offering, managed by Jefferies and Leerink Partners with Wedbush PacGrow as co-manager, is expected to close on November 12, 2024.
Travere Therapeutics (Nasdaq: TVTX) has announced plans for an underwritten public offering of its common stock. The company will offer all shares, with an additional 30-day option for underwriters to purchase up to 15% more shares. Jefferies and Leerink Partners are serving as joint book-running managers. The offering will be made pursuant to an automatically effective shelf registration statement filed with the SEC on August 1, 2024. The completion, size, and terms of the offering are subject to market conditions and cannot be assured.
Travere Therapeutics (NASDAQ: TVTX) has announced its participation in two major healthcare investor conferences this November. The company will present at the Guggenheim Securities Healthcare Innovation Conference on Monday, November 11, 2024, at 2:30 p.m. ET, and at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 8:30 a.m. GMT. Live webcasts of both presentations will be available on Travere's investor relations website, with replays accessible for up to 30 days after each event.
Travere Therapeutics (NASDAQ: TVTX) reported Q3 2024 financial results, highlighting FILSPARI's full FDA approval as the only non-immunosuppressive treatment for IgAN. Net product sales reached $61.0 million, with FILSPARI contributing $35.6 million. Total revenue was $62.9 million. The company received 505 new patient start forms for FILSPARI during Q3. R&D expenses decreased to $51.7 million from $60.6 million year-over-year. The company reported a net loss of $54.8 million ($0.70 per share) and held $277.4 million in cash and equivalents as of September 30, 2024.
FAQ
What is the current stock price of Travere Therapeutics (TVTX)?
What is the market cap of Travere Therapeutics (TVTX)?
